✍️ Palantir Q3 Deal Summary

Contracts you need to know before the Q3 results

Editor: Emanuele Marabella. This post has first been published on Twitter/X (@arny_trezzi)

PLTR 0.00%↑ recent contractual activity was intense.

Here are the contracts you need to know before the Q3 results:

• $34mn Maven Smart System (MSS) extension to US Centcom;

• $30mn IRS call against an existing blanket purchase agreement;

• 5y extension with WesTrac;

• 5y contract with CAZ Investments for AIP;

• Azule Energy (BP + Eni JV) partnership;

• JD Power expansion to leverage AIP in the automotive industry;

• Policlinico Gemelli partnership;

• Concordance expansion to launch a Surgence (OS for Healthcare Supply Chain);

• Pwc partnership to provide antifraud to the Police of the City of London;

• Babcock deal to leverage AIP;

• DoD spectrum coordination workflow automation (5G);

• Carahsoft expansion for Apollo in the Public Sector;

• SpecterOps partnership to provide FedStart;

• Agora expansion to Energy;

• AirMatrix (Canadese startup) partnership.

Meanwhile in Q4:

• $250mn contract with the Army for JADC2;

• $61mn contract with the National Institutes of Health;

• $17mn contract with the Spanish Ministry of Defense;

• £1.5mn contract to provide UK Government with Trade Analytics Solution (6m);

• $6mn contract from the US Office of Medical Services;

• Pwc Global Alliance.

You can compare this with the Q2 Deal Summary:

✍️ Palantir Q2 Deals Summary

Yours,
Arny

You can reach me at:

• Twitter X: @arny_trezzi

• YouTube: arny_trezzi

• Patreon: arnytrezzi

DISCLAIMER:

Palantir Bullets is a publisher of financial information, not an investment advisor. Palantir Bullets does not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient. Palantir Bullets does not guarantee the accuracy or completeness of the information provided on this page. All statements and expressions herein are the sole opinion of the author or paid advertiser.

THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL INVESTMENT ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION

No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.

The author, publisher or insiders of the publisher may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.

Any projections, market outlooks or estimates herein are forward-looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and Palantir Bullets undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.

Palantir Bullets does not accept any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.

By using the Site or any related social media account, you are indicating your consent and agreement to this disclaimer and our terms of use. Unauthorized reproduction of this newsletter or its contents by photocopy, facsimile or any other means is illegal and punishable by law.